@article{ccc29eba7ffc4c7ca7d377221b2255ce,
title = "Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19",
abstract = "Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore, a trial giving fenofibrate to patients with corona virus infection is recommended.",
keywords = "Adult, Aging/blood, Betacoronavirus/physiology, COVID-19, Child, Coronavirus Infections/drug therapy, Drug Repositioning, Fenofibrate/pharmacology, Humans, Hypercholesterolemia/blood, Hypertension/blood, Hypolipidemic Agents/pharmacology, PPAR alpha/antagonists & inhibitors, Pandemics, Pneumonia, Viral/drug therapy, SARS-CoV-2, Sulfoglycosphingolipids/blood, Virus Internalization, COVID-19 Drug Treatment",
author = "Karsten Buschard",
note = "Copyright {\textcopyright} 2020 Elsevier Ltd. All rights reserved.",
year = "2020",
month = oct,
doi = "10.1016/j.mehy.2020.110127",
language = "English",
volume = "143",
pages = "110127",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
}